Drug Profile
Research programme: ocular therapeutics - Novaliq
Alternative Names: Nov-03; Nov-04; Nov-05; Nov-07Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Novaliq
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Dry eyes; Glaucoma; Retinal disorders
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Dry-eyes in Germany
- 28 Nov 2020 No recent reports of development identified for preclinical development in Glaucoma in Germany
- 28 Nov 2020 No recent reports of development identified for research development in Retinal-disorders in Germany